CoChat
Sign Up
Cited by 177Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Open access
Tang, Bixia, Yan, Xieqiao, Sheng, Xinan, Si, Lu, Cui, Chuanliang, Kong, Yan, Mao, Lili, Lian, Bin, Bai, Xue, Wang, Xuan, Li, Siming, Zhou, Li, Yu, Jiayi, Dai, Jie, Wang, Kai, Hu, Jinwei, Dong, Lihou, Song, Haifeng, Wu, Hai, Feng, Hui, Yao, Sheng, Chi, Zhihong, Guo, Jun·2019·Journal of Hematology & Oncology
DOI 10.1186/s13045-018-0693-2PMC PMC6332582
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy. PATIENTS AND METHODS: In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria. RESULTS: Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3- CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB). CONCLUSION: JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology. TRIAL REGISTRATION: Clinical Trial ID: NCT02836795 , registered July 19, 2016, retrospectively registered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-018-0693-2

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Antitumor activity of JS001. Clinical response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigators every 8 weeks. a The percentage of sum of diameters of target lesions over baseline measurement during JS001 treatment is shown for each subject over time in the spider plot. Responses were durable in most patients, as the median duration of response was 5.6 months (range from 1.8 to 17.7+ months). b Waterfall plot of best percentage reduction in tumor burden from baseline is shown. Prior lines of treatment were marked by color for each subject. Seven out of 8 responding subjects had received at least two prior systemic treatments
Fig. 1 Antitumor activity of JS001. Clinical response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigators every 8 weeks. a The percentage of sum of diameters of target lesions over baseline measurement during JS001 treatment is shown for each subject over time in the spider plot. Responses were durable in most patients, as the median duration of response was 5.6 months (range from 1.8 to 17.7+ months). b Waterfall plot of best percentage reduction in tumor burden from baseline is shown. Prior lines of treatment were marked by color for each subject. Seven out of 8 responding subjects had received at least two prior systemic treatmentsCC BY · PubMed Central
Fig. 2 Survival after JS001 treatment. a Progression-free survival (PFS) of subjects by histology. b Overall survival (OS) of subjects by histology. Percentages of survival patients are shown at indicated time points. Numbers of patients at risk at indicated time points are shown below the x-axis
Fig. 2 Survival after JS001 treatment. a Progression-free survival (PFS) of subjects by histology. b Overall survival (OS) of subjects by histology. Percentages of survival patients are shown at indicated time points. Numbers of patients at risk at indicated time points are shown below the x-axisCC BY · PubMed Central
Fig. 3 Pharmacodynamic readouts of JS001. a PD-1 receptor occupancy (RO) was determined as the percentage of receptor bound JS001 to total PD-1 on activated lymphocytes (CD3+ CD45RA−) from the peripheral blood by flow cytometry analysis. RO of responders (CR + PR + SD) and non-responders (PD) are shown. b The frequency of activated CD8+ T cells (CD3+ CD8+ CD45RA−) over time are shown in clinical responders and non-responders
Fig. 3 Pharmacodynamic readouts of JS001. a PD-1 receptor occupancy (RO) was determined as the percentage of receptor bound JS001 to total PD-1 on activated lymphocytes (CD3+ CD45RA−) from the peripheral blood by flow cytometry analysis. RO of responders (CR + PR + SD) and non-responders (PD) are shown. b The frequency of activated CD8+ T cells (CD3+ CD8+ CD45RA−) over time are shown in clinical responders and non-respondersCC BY · PubMed Central
Fig. 4 Correlation of PD-L1 expression by IHC staining in tumor biopsy with clinical efficacy. a High (> 50%) (n = 7), medium (1–50%) (n = 9), and low (< 1%) (n = 12) PD-L1 expression subgroups determined by anti-PD-L1 (SP142) IHC staining on tumor cells are compared for clinical response. b PFS of subjects by PD-L1 expression. PD-L1+ subjects showed significant PFS benefit than PD-L1− subjects, HR = 0.36 (95% CI 0.14–0.93), p = 0.034. c OS of subjects by PD-L1 expression. Percentages of survival patients are shown at indicated time points. Numbers of patients at risk at indicated time points are shown below the x-axis
Fig. 4 Correlation of PD-L1 expression by IHC staining in tumor biopsy with clinical efficacy. a High (> 50%) (n = 7), medium (1–50%) (n = 9), and low (< 1%) (n = 12) PD-L1 expression subgroups determined by anti-PD-L1 (SP142) IHC staining on tumor cells are compared for clinical response. b PFS of subjects by PD-L1 expression. PD-L1+ subjects showed significant PFS benefit than PD-L1− subjects, HR = 0.36 (95% CI 0.14–0.93), p = 0.034. c OS of subjects by PD-L1 expression. Percentages of survival patients are shown at indicated time points. Numbers of patients at risk at indicated time points are shown below the x-axisCC BY · PubMed Central
Fig. 5 Correlation of biomarkers or subgroups with clinical efficacy. Subgroups by age, gender, PD-L1 expression on tumor cells, the presence of CD8+ TILs, ECOG performance score, LDH serum levels, baseline tumor burden, and prior lines of treatment are compared for clinical response to JS001 treatment. PD-L1-positive status was defined as the presence of membrane staining of any intensity in ≥ 1% of tumor cells by SP142 IHC staining. Upper limit of normal (ULN) for LDH serum level is 250 U/L. Baseline tumor burden was represented by sum of diameters of target lesion(s) per RECISTv1.1, and 100 mm was used as a cutoff
Fig. 5 Correlation of biomarkers or subgroups with clinical efficacy. Subgroups by age, gender, PD-L1 expression on tumor cells, the presence of CD8+ TILs, ECOG performance score, LDH serum levels, baseline tumor burden, and prior lines of treatment are compared for clinical response to JS001 treatment. PD-L1-positive status was defined as the presence of membrane staining of any intensity in ≥ 1% of tumor cells by SP142 IHC staining. Upper limit of normal (ULN) for LDH serum level is 250 U/L. Baseline tumor burden was represented by sum of diameters of target lesion(s) per RECISTv1.1, and 100 mm was used as a cutoffCC BY · PubMed Central
Fig. 6 Correlation of TMB with objective response and overall survival upon JS001 treatment. Genomic profiling was performed by next-generation sequencing with a 450 cancer-related gene panel on both FFPE tumor and paired peripheral blood samples from 23 available subjects. The TMB was calculated by summing up somatic mutations within the coding regions examined the NGS panel. a Correlation of TMB with clinical response. Six mutations per Mb was used as a cutoff. b Correlation of TMB, PD-L1 status, and clinical response
Fig. 6 Correlation of TMB with objective response and overall survival upon JS001 treatment. Genomic profiling was performed by next-generation sequencing with a 450 cancer-related gene panel on both FFPE tumor and paired peripheral blood samples from 23 available subjects. The TMB was calculated by summing up somatic mutations within the coding regions examined the NGS panel. a Correlation of TMB with clinical response. Six mutations per Mb was used as a cutoff. b Correlation of TMB, PD-L1 status, and clinical responseCC BY · PubMed Central
Fig. 7 Genomic profiling of enrolled subjects. Genomic profiling was performed by next-generation sequencing with a 450 cancer-related gene panel on both FFPE tumor and paired peripheral blood samples from 23 available subjects. Genomic alterations including SNV, short and long INDELs, CNV, and gene rearrangement and fusions were assessed
Fig. 7 Genomic profiling of enrolled subjects. Genomic profiling was performed by next-generation sequencing with a 450 cancer-related gene panel on both FFPE tumor and paired peripheral blood samples from 23 available subjects. Genomic alterations including SNV, short and long INDELs, CNV, and gene rearrangement and fusions were assessedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

Sorted by citations

See all 177

Related

Metadata

Authors
Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., Mao, L., Lian, B., Bai, X., Wang, X., Li, S., Zhou, L., Yu, J., Dai, J., Wang, K., Hu, J., Dong, L., Song, H., Wu, H., Feng, H., Yao, S., Chi, Z., & Guo, J.
Affiliations
  • Peking University Cancer Hospital (CN)
  • Beijing Radiation Center (CN)
  • Junshi Biosciences (China) (CN)
Corresponding author
  • Chi, Zhihong
  • Guo, Jun
ORCID
Venue
Journal of Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Published
2019-01-14
Volume
12
Issue
1
Pages
7-7
ISSN
1756-8722 (ISSN-L)
DOI
10.1186/s13045-018-0693-2
PMC
PMC6332582
OpenAlex
W2923110622
Cited by
169
References
32
Citations by year
2026: 5 · 2025: 12 · 2024: 21 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 26 · 2019: 12
FWCI
11.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support (ZYLX201603)
  • National Science &Technology Major Project “Key New Drug Creation and Manufacturing Program” (2015ZX09102017)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-PD-1, advanced melanoma, urothelial carcinoma, renal cell carcinoma, immune checkpoint blockade, safety and tolerability, objective response rate, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, acral melanoma, mucosal melanoma, predictive biomarkers, dose escalation, dose expansion, natural killer cells
MeSH terms
Progression-Free Survival, Adult, Aged, Antineoplastic Agents, Biopsy, Carcinoma, Renal Cell, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Immunoglobulin G, Infusions, Intravenous, Lymphocyte Activation, Male, Melanoma, Middle Aged, Skin Neoplasms, Biomarkers, Tumor, Urologic Neoplasms, CD8-Positive T-Lymphocytes, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review